AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03668665
Drug: Ready Medical Post Treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed
Trial: NCT01037595
Drug: turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: turmeric 500 md tid orally for 8 weeks
Trial: NCT02382640
Drug: Febuxostat XR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat extended-release (XR) capsules
Trial: NCT00458185
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01037595
Drug: turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tid orally for 8 weeks
Trial: NCT05167370
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
Trial: NCT04638881
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
Trial: NCT01989689
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 50mg twice weekly
Trial: NCT02111551
Drug: DMXB-A 150 mg
RxNorm normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02111551
Drug: DMXB-A 75 mg
RxNorm normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232308
Drug: Nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Trial: NCT02232308
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Trial: NCT03026166
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion
Trial: NCT03026166
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion
Trial: NCT03026166
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT00712881
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered per dose and schedule specified in the arm description.
Trial: NCT00712881
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered per dose and schedule specified in the arm description.
Trial: NCT00118898
Drug: Abacavir/Lamivudine
RxNorm normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg abacavir/300 mg lamivudine tablet taken orally daily
Trial: NCT00118898
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg tablet taken orally daily
Trial: NCT00118898
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg tablet taken orally daily
Trial: NCT00118898
Drug: Emtricitabine/Tenofovir disoproxil fumarate
RxNorm normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
Trial: NCT00118898
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg tablet taken orally daily
Trial: NCT00118898
Drug: Abacavir/Lamivudine placebo
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo tablet taken orally daily
Trial: NCT00118898
Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally daily
Trial: NCT03662191
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bioavailability study
Trial: NCT02261948
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Trial: NCT04570865
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Trial: NCT02399449
Drug: Brand sodium ferric gluconate
RxNorm normalized name: FERRIC NA GLUCONATE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: brand product
Trial: NCT02399449
Drug: Generic sodium ferric gluconate
RxNorm normalized name: FERRIC NA GLUCONATE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: generic product
Trial: NCT03470805
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
Trial: NCT00968981
Drug: GDC-0449
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral repeating dose
Trial: NCT00968981
Drug: GDC-0449
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three times weekly oral repeating dose
Trial: NCT00968981
Drug: GDC-0449
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once weekly oral repeating dose
Trial: NCT03014895
Drug: E3112
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02233296
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 discrete doses separated by 6 days.
Trial: NCT00643825
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
Trial: NCT00643825
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Observation till Progression then rechallenging with TMZ
Trial: NCT01461317
Drug: Etrolizumab
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive etrolizumab at a dose of 100 mg.
Trial: NCT03541369
Drug: AMG 427
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
Trial: NCT00119691
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Trial: NCT00965926
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01747564
Drug: YM178 (mirabegron)
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03843541
Drug: N-acetylcysteine (NAC) 600 mg
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC will be administered twice a day, morning and evening, during treatment period.
Trial: NCT03843541
Drug: Ambroxol hydrochloride 30 mg
RxNorm normalized name: Ambroxol hydrochloride 30 mg oral tablet
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
Trial: NCT00952796
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400mg once daily (IV form, 60minutes)
Trial: NCT00952796
Drug: ampicillin/sulbactam
RxNorm normalized name: AMPICILLIN/SULBACTAM
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
Trial: NCT00312260
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
Trial: NCT00312260
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
Trial: NCT04392128
Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
RxNorm normalized name: hydroxychloroquine sulfate 200 MG [Plaquenil]
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
Trial: NCT00385411
Drug: valproate microgranules
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 to 30 mg/kg/day
Trial: NCT00806234
Drug: Aripiprazole or Perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
Trial: NCT00806234
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
Trial: NCT00806234
Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
Trial: NCT01337674
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previously prescribed daily dose of open-label metoprolol for the duration of the study
Trial: NCT01337674
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previously prescribed daily dose of open-label amlodipine for the duration of the study
Trial: NCT04063124
Drug: Dasatinib + Quercetin
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
Trial: NCT00392197
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 or 2 times a day, p.o., 6 - 24mg a day
Trial: NCT05330000
Drug: 4 mg/kg Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
Trial: NCT05330000
Drug: 6 mg/kg Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
Trial: NCT00733174
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02115659
Drug: Triptolide-Containing Formulation
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
DrugBank: Triptolide (DB12025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
Trial: NCT00658437
Drug: CY-503
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solution for subcutaneous injection, 350 ng twice weekly
Trial: NCT00070317
Drug: Isosulfan Blue
RxNorm normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo lymphangiography using isosulfan blue or methylene blue
Trial: NCT00070317
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo lymphangiography using isosulfan blue or methylene blue
Trial: NCT00222365
Drug: Arnica montana, 5 CH
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00737204
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
Trial: NCT02920450
Drug: Gedatolisib
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg
Trial: NCT02920450
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
Trial: NCT02920450
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
Trial: NCT01712009
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00209807
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10 mg/d for 6 weeks
Trial: NCT00209807
Drug: Reboxetine
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8 mg/d for 6 weeks
Trial: NCT03350334
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-operative Duloxetine administration
Trial: NCT02240108
Drug: Rifaximin EIR
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Trial: NCT04414579
Drug: Faster Insulin Aspart (Fiasp®)
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
Trial: NCT01573806
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide, dosed subcutaneously every 12 hours for 4 doses
Trial: NCT01573806
Drug: Exenatide vehicle
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
Trial: NCT01878929
Drug: Allergen(Tree, Grass, Weeds)
RxNorm normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Greer is manufacture of all allergen extract used in this study.
Trial: NCT01991275
Drug: The intrathecal morphine injection
RxNorm normalized name: morphine Injection
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single injection of morphine intrathecally
Trial: NCT03530631
Drug: Adderall
RxNorm normalized name: Adderall
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered Adderall
Trial: NCT03072290
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
Trial: NCT00880074
Drug: Fluorothymidine F-18
RxNorm normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo fluorine F-18 fluorothymidine PET
Trial: NCT01317966
Drug: rhIL-11
RxNorm normalized name: Oprelvekin (rhIL-11)
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
Trial: NCT03072290
Drug: lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
Trial: NCT03987074
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
Trial: NCT03987074
Drug: Firsocostat
RxNorm normalized name: Firsocostat
DrugBank: Firsocostat (DB16166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT03987074
Drug: Cilofexor
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02790632
Drug: EG-1962 (nimodipine microparticles)
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
Trial: NCT02790632
Drug: Enteral Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
Trial: NCT04494399
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day course of daily subcutaneous injection of interferon β-1b 16 million IU